Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 81 entries
Sorted by: Best Match Show Resources per page
Death and Neurological Devastation From Intrathecal Vinca Alkaloids.

P & T : a peer-reviewed journal for formulary management

Grissinger M.
PMID: 27504060
P T. 2016 Aug;41(8):464-525.

Inadvertent intrathecal vincristine administration causes fatalities.

Cite
Grissinger M. Death and Neurological Devastation From Intrathecal Vinca Alkaloids. P T. 2016;41(8):464-525
Grissinger, M. (2016). Death and Neurological Devastation From Intrathecal Vinca Alkaloids. P & T : a peer-reviewed journal for formulary management, 41(8), 464-525.
Grissinger, Matthew. "Death and Neurological Devastation From Intrathecal Vinca Alkaloids." P & T : a peer-reviewed journal for formulary management vol. 41,8 (2016): 464-525.
Grissinger M. Death and Neurological Devastation From Intrathecal Vinca Alkaloids. P T. 2016 Aug;41(8):464-525. PMID: 27504060; PMCID: PMC4959612.
Copy Download .nbib Format: NLM
Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics.

Translational oncology

Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, Rödel F, Wezel F, Haferkamp A, Cinatl J.
PMID: 26055179
Transl Oncol. 2015 Jun;8(3):210-6. doi: 10.1016/j.tranon.2015.04.002.

Combination chemotherapy with gemcitabine and cisplatin in patients with metastatic urothelial cancer of the bladder frequently results in the development of acquired drug resistance. Availability of cell culture models with acquired resistance could help to identify candidate treatments for...

Cite
Vallo S, Michaelis M, Rothweiler F, et al. Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. Transl Oncol. 2015;8(3):210-6doi: 10.1016/j.tranon.2015.04.002.
Vallo, S., Michaelis, M., Rothweiler, F., Bartsch, G., Gust, K. M., Limbart, D. M., Rödel, F., Wezel, F., Haferkamp, A., & Cinatl, J. (2015). Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. Translational oncology, 8(3), 210-6. https://doi.org/10.1016/j.tranon.2015.04.002
Vallo, Stefan, et al. "Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics." Translational oncology vol. 8,3 (2015): 210-6. doi: https://doi.org/10.1016/j.tranon.2015.04.002
Vallo S, Michaelis M, Rothweiler F, Bartsch G, Gust KM, Limbart DM, Rödel F, Wezel F, Haferkamp A, Cinatl J. Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics. Transl Oncol. 2015 Jun;8(3):210-6. doi: 10.1016/j.tranon.2015.04.002. PMID: 26055179; PMCID: PMC4487788.
Copy Download .nbib Format: NLM
Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor.

Translational oncology

Tuma MC, Malikzay A, Ouyang X, Surguladze D, Fleming J, Mitelman S, Camara M, Finnerty B, Doody J, Chekler EL, Kussie P, Tonra JR.
PMID: 20885894
Transl Oncol. 2010 Oct 01;3(5):318-25. doi: 10.1593/tlo.10160.

Microtubules are a well-validated target for anticancer therapy. Molecules that bind tubulin affect dynamic instability of microtubules causing mitotic arrest of proliferating cells, leading to cell death and tumor growth inhibition. Natural antitubulin agents such as taxanes and Vinca...

Cite
Tuma MC, Malikzay A, Ouyang X, et al. Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor. Transl Oncol. 2010;3(5):318-25doi: 10.1593/tlo.10160.
Tuma, M. C., Malikzay, A., Ouyang, X., Surguladze, D., Fleming, J., Mitelman, S., Camara, M., Finnerty, B., Doody, J., Chekler, E. L., Kussie, P., & Tonra, J. R. (2010). Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor. Translational oncology, 3(5), 318-25. https://doi.org/10.1593/tlo.10160
Tuma, Maria Carolina, et al. "Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor." Translational oncology vol. 3,5 (2010): 318-25. doi: https://doi.org/10.1593/tlo.10160
Tuma MC, Malikzay A, Ouyang X, Surguladze D, Fleming J, Mitelman S, Camara M, Finnerty B, Doody J, Chekler EL, Kussie P, Tonra JR. Antitumor Activity of IMC-038525, a Novel Oral Tubulin Polymerization Inhibitor. Transl Oncol. 2010 Oct 01;3(5):318-25. doi: 10.1593/tlo.10160. PMID: 20885894; PMCID: PMC2935635.
Copy Download .nbib Format: NLM
Selective drug efflux in multidrug-resistant immunoblastic B lymphoma cells with overexpressed P-glycoprotein.

Environmental toxicology and pharmacology

Chao CC.
PMID: 21781664
Environ Toxicol Pharmacol. 1996 Feb 15;1(1):63-72. doi: 10.1016/1382-6689(95)00010-0.

Multidrug-resistant (MDR) sublines of the immunoblastic B lymphoma cell line were established by sequentially selecting in increasing concentrations of vincristine or adriamycin. The vincristine- and adriamycin-resistant cell lines, HOB1/VCR and HOB1/ADR, respectively, demonstrated resistance to a wide spectrum of...

Cite
Chao CC. Selective drug efflux in multidrug-resistant immunoblastic B lymphoma cells with overexpressed P-glycoprotein. Environ Toxicol Pharmacol. 1996;1(1):63-72doi: 10.1016/1382-6689(95)00010-0.
Chao, C. C. (1996). Selective drug efflux in multidrug-resistant immunoblastic B lymphoma cells with overexpressed P-glycoprotein. Environmental toxicology and pharmacology, 1(1), 63-72. https://doi.org/10.1016/1382-6689(95)00010-0
Chao, C C. "Selective drug efflux in multidrug-resistant immunoblastic B lymphoma cells with overexpressed P-glycoprotein." Environmental toxicology and pharmacology vol. 1,1 (1996): 63-72. doi: https://doi.org/10.1016/1382-6689(95)00010-0
Chao CC. Selective drug efflux in multidrug-resistant immunoblastic B lymphoma cells with overexpressed P-glycoprotein. Environ Toxicol Pharmacol. 1996 Feb 15;1(1):63-72. doi: 10.1016/1382-6689(95)00010-0. PMID: 21781664.
Copy Download .nbib Format: NLM
Mapping Mitotic Death: Functional Integration of Mitochondria, Spindle Assembly Checkpoint and Apoptosis.

Frontiers in cell and developmental biology

Ruan W, Lim HH, Surana U.
PMID: 30687704
Front Cell Dev Biol. 2019 Jan 10;6:177. doi: 10.3389/fcell.2018.00177. eCollection 2018.

Targeting the mitotic pathways of rapidly proliferating tumor cells has been an effective strategy in traditional cancer therapy. Chemotherapeutics such as taxanes and vinca alkaloids, which disrupt microtubule function, have enjoyed clinical success; however, the accompanying side effects, toxicity...

Cite
Ruan W, Lim HH, Surana U. Mapping Mitotic Death: Functional Integration of Mitochondria, Spindle Assembly Checkpoint and Apoptosis. Front Cell Dev Biol. 2019;6:177doi: 10.3389/fcell.2018.00177.
Ruan, W., Lim, H. H., & Surana, U. (2018). Mapping Mitotic Death: Functional Integration of Mitochondria, Spindle Assembly Checkpoint and Apoptosis. Frontiers in cell and developmental biology, 6177. https://doi.org/10.3389/fcell.2018.00177
Ruan, Weimei, et al. "Mapping Mitotic Death: Functional Integration of Mitochondria, Spindle Assembly Checkpoint and Apoptosis." Frontiers in cell and developmental biology vol. 6 (2018): 177. doi: https://doi.org/10.3389/fcell.2018.00177
Ruan W, Lim HH, Surana U. Mapping Mitotic Death: Functional Integration of Mitochondria, Spindle Assembly Checkpoint and Apoptosis. Front Cell Dev Biol. 2019 Jan 10;6:177. doi: 10.3389/fcell.2018.00177. eCollection 2018. PMID: 30687704; PMCID: PMC6335265.
Copy Download .nbib Format: NLM
βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies.

Biochimica et biophysica acta. Reviews on cancer

Kanakkanthara A, Miller JH.
PMID: 34364992
Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188607. doi: 10.1016/j.bbcan.2021.188607. Epub 2021 Aug 06.

Class III β-tubulin (βIII-tubulin) is frequently overexpressed in human tumors and is associated with resistance to microtubule-targeting agents, tumor aggressiveness, and poor patient outcome. Understanding the mechanisms regulating βIII-tubulin expression and the varied functions βIII-tubulin may have in different...

Cite
Kanakkanthara A, Miller JH. βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies. Biochim Biophys Acta Rev Cancer. 2021;1876(2):188607doi: 10.1016/j.bbcan.2021.188607.
Kanakkanthara, A., & Miller, J. H. (2021). βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies. Biochimica et biophysica acta. Reviews on cancer, 1876(2), 188607. https://doi.org/10.1016/j.bbcan.2021.188607
Kanakkanthara, Arun, and Miller, John H. "βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies." Biochimica et biophysica acta. Reviews on cancer vol. 1876,2 (2021): 188607. doi: https://doi.org/10.1016/j.bbcan.2021.188607
Kanakkanthara A, Miller JH. βIII-tubulin overexpression in cancer: Causes, consequences, and potential therapies. Biochim Biophys Acta Rev Cancer. 2021 Dec;1876(2):188607. doi: 10.1016/j.bbcan.2021.188607. Epub 2021 Aug 06. PMID: 34364992.
Copy Download .nbib Format: NLM
10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids.

ACS medicinal chemistry letters

Gotoh H, Duncan KK, Robertson WM, Boger DL.
PMID: 22247789
ACS Med Chem Lett. 2011 Dec 08;2(12):948-952. doi: 10.1021/ml200236a.

A study on the impact of catharanthine C10 and C12 indole substituents on the biomimetic Fe(III)-mediated coupling with vindoline led to the discovery and characterization of two new and substantially more potent derivatives, 10'-fluorovinblastine and 10'-fluorovincristine. In addition to...

Cite
Gotoh H, Duncan KK, Robertson WM, et al. 10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids. ACS Med Chem Lett. 2011;2(12):948-952doi: 10.1021/ml200236a.
Gotoh, H., Duncan, K. K., Robertson, W. M., & Boger, D. L. (2011). 10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids. ACS medicinal chemistry letters, 2(12), 948-952. https://doi.org/10.1021/ml200236a
Gotoh, Hiroaki, et al. "10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids." ACS medicinal chemistry letters vol. 2,12 (2011): 948-952. doi: https://doi.org/10.1021/ml200236a
Gotoh H, Duncan KK, Robertson WM, Boger DL. 10'-Fluorovinblastine and 10'-Fluorovincristine: Synthesis of a Key Series of Modified Vinca Alkaloids. ACS Med Chem Lett. 2011 Dec 08;2(12):948-952. doi: 10.1021/ml200236a. PMID: 22247789; PMCID: PMC3254105.
Copy Download .nbib Format: NLM
Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer.

Acta pharmaceutica Sinica. B

Jiang W, Cai G, Hu P, Wang Y.
PMID: 34900526
Acta Pharm Sin B. 2021 Nov;11(11):3406-3416. doi: 10.1016/j.apsb.2021.02.003. Epub 2021 Feb 10.

Non-small cell lung cancer is recognized as the deadliest cancer across the globe. In some areas, it is more common in women than even breast and cervical cancer. Its rise, vaulted by smoking habits and increasing air pollution, has...

Cite
Jiang W, Cai G, Hu P, et al. Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer. Acta Pharm Sin B. 2021;11(11):3406-3416doi: 10.1016/j.apsb.2021.02.003.
Jiang, W., Cai, G., Hu, P., & Wang, Y. (2021). Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer. Acta pharmaceutica Sinica. B, 11(11), 3406-3416. https://doi.org/10.1016/j.apsb.2021.02.003
Jiang, Wenxiao, et al. "Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer." Acta pharmaceutica Sinica. B vol. 11,11 (2021): 3406-3416. doi: https://doi.org/10.1016/j.apsb.2021.02.003
Jiang W, Cai G, Hu P, Wang Y. Personalized medicine of non-gene-specific chemotherapies for non-small cell lung cancer. Acta Pharm Sin B. 2021 Nov;11(11):3406-3416. doi: 10.1016/j.apsb.2021.02.003. Epub 2021 Feb 10. PMID: 34900526; PMCID: PMC8642451.
Copy Download .nbib Format: NLM
Chemotherapy-induced peripheral neuropathy and rehabilitation: A review.

Seminars in oncology

Zhang S.
PMID: 34607709
Semin Oncol. 2021 Jun;48(3):193-207. doi: 10.1053/j.seminoncol.2021.09.004. Epub 2021 Sep 22.

Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication after chemotherapy that can damage the sensory, motor, autonomic, or cranial nerves in approximately 30%-60% of patients with cancer. CIPN can lead to detrimental dose modifications and/or premature chemotherapy discontinuation due...

Cite
Zhang S. Chemotherapy-induced peripheral neuropathy and rehabilitation: A review. Semin Oncol. 2021;48(3):193-207doi: 10.1053/j.seminoncol.2021.09.004.
Zhang, S. (2021). Chemotherapy-induced peripheral neuropathy and rehabilitation: A review. Seminars in oncology, 48(3), 193-207. https://doi.org/10.1053/j.seminoncol.2021.09.004
Zhang, Shangming. "Chemotherapy-induced peripheral neuropathy and rehabilitation: A review." Seminars in oncology vol. 48,3 (2021): 193-207. doi: https://doi.org/10.1053/j.seminoncol.2021.09.004
Zhang S. Chemotherapy-induced peripheral neuropathy and rehabilitation: A review. Semin Oncol. 2021 Jun;48(3):193-207. doi: 10.1053/j.seminoncol.2021.09.004. Epub 2021 Sep 22. PMID: 34607709.
Copy Download .nbib Format: NLM
Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology.

Frontiers in pharmacology

Bernsen EC, Hagleitner MM, Kouwenberg TW, Hanff LM.
PMID: 32848787
Front Pharmacol. 2020 Aug 05;11:1184. doi: 10.3389/fphar.2020.01184. eCollection 2020.

In the past decades, new cancer treatments have been introduced in pediatric oncology leading to improvement in clinical outcomes and survival rates. However, due to inter-individual differences, some children experience severe chemotherapy-induced toxicities or a poor clinical outcome. An...

Cite
Bernsen EC, Hagleitner MM, Kouwenberg TW, et al. Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology. Front Pharmacol. 2020;11:1184doi: 10.3389/fphar.2020.01184.
Bernsen, E. C., Hagleitner, M. M., Kouwenberg, T. W., & Hanff, L. M. (2020). Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology. Frontiers in pharmacology, 111184. https://doi.org/10.3389/fphar.2020.01184
Bernsen, Emma C, et al. "Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology." Frontiers in pharmacology vol. 11 (2020): 1184. doi: https://doi.org/10.3389/fphar.2020.01184
Bernsen EC, Hagleitner MM, Kouwenberg TW, Hanff LM. Pharmacogenomics as a Tool to Limit Acute and Long-Term Adverse Effects of Chemotherapeutics: An Update in Pediatric Oncology. Front Pharmacol. 2020 Aug 05;11:1184. doi: 10.3389/fphar.2020.01184. eCollection 2020. PMID: 32848787; PMCID: PMC7421781.
Copy Download .nbib Format: NLM
Motor Performance in Children Diagnosed with Cancer: A Longitudinal Observational Study.

Children (Basel, Switzerland)

Hamari L, Lähteenmäki PM, Pukkila H, Arola M, Axelin A, Salanterä S, Järvelä LS.
PMID: 32824254
Children (Basel). 2020 Aug 15;7(8). doi: 10.3390/children7080098.

Children with cancer are dealing with different side and long-term effects caused by cancer and its treatments, like vinca-alkaloids, which may have negative effects on motor performance. However, the affected areas of motor performance (aiming and catching, balance, manual...

Cite
Hamari L, Lähteenmäki PM, Pukkila H, et al. Motor Performance in Children Diagnosed with Cancer: A Longitudinal Observational Study. Children (Basel). 2020;7(8)doi: 10.3390/children7080098.
Hamari, L., Lähteenmäki, P. M., Pukkila, H., Arola, M., Axelin, A., Salanterä, S., & Järvelä, L. S. (2020). Motor Performance in Children Diagnosed with Cancer: A Longitudinal Observational Study. Children (Basel, Switzerland), 7(8), . https://doi.org/10.3390/children7080098
Hamari, Lotta, et al. "Motor Performance in Children Diagnosed with Cancer: A Longitudinal Observational Study." Children (Basel, Switzerland) vol. 7,8 (2020). doi: https://doi.org/10.3390/children7080098
Hamari L, Lähteenmäki PM, Pukkila H, Arola M, Axelin A, Salanterä S, Järvelä LS. Motor Performance in Children Diagnosed with Cancer: A Longitudinal Observational Study. Children (Basel). 2020 Aug 15;7(8). doi: 10.3390/children7080098. PMID: 32824254; PMCID: PMC7464043.
Copy Download .nbib Format: NLM
Second-Generation Antimitotics in Cancer Clinical Trials.

Pharmaceutics

Novais P, Silva PMA, Amorim I, Bousbaa H.
PMID: 34371703
Pharmaceutics. 2021 Jul 02;13(7). doi: 10.3390/pharmaceutics13071011.

Mitosis represents a promising target to block cancer cell proliferation. Classical antimitotics, mainly microtubule-targeting agents (MTAs), such as taxanes and vinca alkaloids, are amongst the most successful anticancer drugs. By disrupting microtubules, they activate the spindle assembly checkpoint (SAC),...

Cite
Novais P, Silva PMA, Amorim I, et al. Second-Generation Antimitotics in Cancer Clinical Trials. Pharmaceutics. 2021;13(7)doi: 10.3390/pharmaceutics13071011.
Novais, P., Silva, P. M. A., Amorim, I., & Bousbaa, H. (2021). Second-Generation Antimitotics in Cancer Clinical Trials. Pharmaceutics, 13(7), . https://doi.org/10.3390/pharmaceutics13071011
Novais, Pedro, et al. "Second-Generation Antimitotics in Cancer Clinical Trials." Pharmaceutics vol. 13,7 (2021). doi: https://doi.org/10.3390/pharmaceutics13071011
Novais P, Silva PMA, Amorim I, Bousbaa H. Second-Generation Antimitotics in Cancer Clinical Trials. Pharmaceutics. 2021 Jul 02;13(7). doi: 10.3390/pharmaceutics13071011. PMID: 34371703; PMCID: PMC8309102.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 81 entries